Treatment of Multiple Endocrine Neoplasia Type 2A with Medullary Thyroid Cancer and No Lymph Node Metastases

This protocol covers the management of patients with Multiple endocrine neoplasia type 2A (MEN2A) presenting with medullary thyroid carcinoma (MTC) where pre-operative ultrasound shows no evidence of neck lymph node involvement and no distant metastases have been identified.

Clinical scenario

Patients with sporadic or hereditary MTC — including those with MEN2A — in whom ultrasound examination of the neck reveals no lymph node metastases and staging shows no distant spread. This specific presentation determines the surgical scope.

Treatment approach (partial)

Standard management involves a defined surgical intervention targeting the thyroid gland together with dissection of a specific cervical lymph node compartment. The complete scope, laterality considerations, and any additional steps are described in the full protocol.

Primary clinical goal

The central measure of success is normalization of basal serum calcitonin to a normal or undetectable level postoperatively, establishing biochemical cure.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1089/thy.2014.0335

Total thyroidectomy and dissection of cervical lymph node compartments, depending on serum Ctn levels and US findings, is standard treatment for patients with sporadic or hereditary MTC.
Patients with MTC and no evidence of neck lymph node metastases by US examination and no evidence of distant metastases should have a total thyroidectomy and dissection of the lymph nodes in the central compartment (level VI).
It should be noted that patients whose basal serum calcitonin level is normal (< 10 pg/mL) following attempted complete lymph node dissection are said to be “biochemically cured” and have a 97.7% survival at 10 years.

View source ↗